Cash Flow Statement

Altimmune (ALT) Non-cash Items (2016 - 2026)

Altimmune (ALT) reported Non-cash Items of $5.5 million for Q1 2026, up 120.42% year-over-year from $2.5 million in Q1 2025, and up 529.09% on a QoQ basis from $877000.0 in Q4 2025.

Altimmune (ALT) has 11 years of Non-cash Items data on file, last reported at $5.5 million in Q1 2026.

  • Quarterly Non-cash Items rose 120.42% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 120.42% YoY) and the FY2025 annual result came in at $877000.0, down 84.98% from the prior year.
  • Non-cash Items climbed to $5.5 million in Q1 2026 per ALT's latest filing, from $877000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $25.7 million in Q4 2022 and bottomed at $3642.0 in Q2 2022.
  • The 5-year median for Non-cash Items is $2.9 million (2024), against an average of $4.7 million.
  • The widest annual swing landed in 2022, when Non-cash Items slumped 99.58%; it then jumped 19834.1% in 2023.
  • Tracing ALT's Non-cash Items over 5 years: stood at $25.7 million in 2022, then plunged by 34.23% to $16.9 million in 2023, then slumped by 65.49% to $5.8 million in 2024, then plunged by 84.98% to $877000.0 in 2025, then soared by 529.09% to $5.5 million in 2026.
  • Per Business Quant, the three latest ALT Non-cash Items figures stand at $5.5 million (Q1 2026), $877000.0 (Q4 2025), and $4.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Altimmune 379.61 Mn 379.61 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 5.52 Mn
Mar 31, 2026 5.52 Mn
Dec 31, 2025 877,000.00
Dec 31, 2025 877,000.00
Sep 30, 2025 4.50 Mn
Sep 30, 2025 4.50 Mn
Jun 30, 2025 4.32 Mn
Jun 30, 2025 4.32 Mn
Mar 31, 2025 2.50 Mn
Mar 31, 2025 2.50 Mn
Dec 31, 2024 5.84 Mn
Dec 31, 2024 5.84 Mn
Sep 30, 2024 4.16 Mn
Sep 30, 2024 4.16 Mn
Jun 30, 2024 3.30 Mn
Jun 30, 2024 3.30 Mn
Mar 31, 2024 2.94 Mn
Mar 31, 2024 2.94 Mn
Dec 31, 2023 16.92 Mn
Dec 31, 2023 16.92 Mn
Sep 30, 2023 239,000.00
Sep 30, 2023 239,000.00
Jun 30, 2023 726,000.00
Jun 30, 2023 726,000.00
Mar 31, 2023 1.84 Mn
Mar 31, 2023 1.84 Mn
Dec 31, 2022 25.72 Mn
Dec 31, 2022 25.72 Mn
Sep 30, 2022 16,975.00
Sep 30, 2022 16,975.00
Jun 30, 2022 3,642.00
Jun 30, 2022 3,642.00
Mar 31, 2022 1.27 Mn
Mar 31, 2022 1.27 Mn
Dec 31, 2021 8.46 Mn
Dec 31, 2021 8.46 Mn
Sep 30, 2021 984,613.00
Sep 30, 2021 984,613.00
Jun 30, 2021 863,736.00
Jun 30, 2021 863,736.00
Mar 31, 2021 773,781.00
Mar 31, 2021 773,781.00
Dec 31, 2020 12.23 Mn
Dec 31, 2020 12.23 Mn
Sep 30, 2020 458,609.00
Sep 30, 2020 458,609.00
Jun 30, 2020 12.80 Mn
Jun 30, 2020 12.80 Mn
Mar 31, 2020 940,809.00
Mar 31, 2020 940,809.00
Dec 31, 2019 289,518.00
Dec 31, 2019 289,518.00
Sep 30, 2019 188,928.00
Sep 30, 2019 188,928.00
Jun 30, 2019 112,944.00
Jun 30, 2019 112,944.00
Mar 31, 2019 66,732.00
Mar 31, 2019 66,732.00
Dec 31, 2018 1.29 Mn
Dec 31, 2018 1.29 Mn
Sep 30, 2018 846,697.00
Sep 30, 2018 846,697.00
Jun 30, 2018 1.20 Mn
Jun 30, 2018 1.20 Mn
Mar 31, 2018 1.78 Mn
Mar 31, 2018 1.78 Mn
Dec 31, 2017 3,324.00
Dec 31, 2017 3,324.00
Sep 30, 2017 883,740.00
Sep 30, 2017 883,740.00
Jun 30, 2017 2.08 Mn
Jun 30, 2017 2.08 Mn
Dec 31, 2016 8.48 Mn
Dec 31, 2016 8.48 Mn